GLP-1 Medications: Complete Guide to GLP-1 Receptor Agonists (2026)

GLP-1 medications are prescription drugs that mimic the hormone glucagon-like peptide-1 to improve blood sugar control and reduce appetite. They are widely used to treat type 2 diabetes and obesity. Originally developed for type 2 diabetes, these drugs have become one of the most prescribed medication classes in the United States, driven by their effectiveness for blood sugar control, weight loss, and cardiovascular protection.

This guide covers every FDA-approved GLP-1 drug available in 2026, how they compare, what they cost, and what’s coming next in the pipeline.

How GLP-1 Medications Work

When you eat, your intestines release GLP-1 naturally. This hormone:

• Stimulates insulin secretion from the pancreas (glucose-dependent — only when blood sugar is elevated)
• Suppresses glucagon — preventing the liver from releasing stored glucose
• Slows gastric emptying — food leaves the stomach more slowly, reducing post-meal glucose spikes
• Signals satiety in the brain — reducing appetite and caloric intake
• GLP-1 receptor agonist drugs bind to the same receptors as natural GLP-1, but last far longer — from 24 hours (daily injections like Victoza) to one week (Ozempic) or even taken as a daily pill (Rybelsus).

Complete List of FDA-Approved GLP-1 Medications (2026)

Drug (Generic)	Brand	Format	Frequency	FDA Indications	Avg. Weight Loss
Liraglutide	Victoza	Injection pen	Daily	T2D, CV risk reduction	~5–6%
Liraglutide 3mg	Saxenda	Injection pen	Daily	Obesity (BMI ≥30)	~8%
Semaglutide	Ozempic	Injection pen	Weekly	T2D, CV risk reduction	~10–14%
Semaglutide 2.4mg	Wegovy	Injection pen	Weekly	Obesity, CV risk reduction	~15–17%
Oral semaglutide	Rybelsus	Oral tablet	Daily	T2D	~4–5%
Tirzepatide (GLP-1/GIP)	Mounjaro	Injection pen	Weekly	T2D	~15–21%
Tirzepatide (GLP-1/GIP)	Zepbound	Injection pen	Weekly	Obesity, sleep apnea	~20–22%
Dulaglutide	Trulicity	Injection pen	Weekly	T2D, CV risk reduction	~3%
Exenatide ER	Bydureon BCise	Injection	Weekly	T2D	~2–3%

Tirzepatide (Mounjaro/Zepbound) is a dual GIP/GLP-1 agonist — technically not a pure GLP-1 drug, but clinically grouped in the same class due to mechanism overlap and similar prescribing patterns.

GLP-1 medications currently available through our pharmacy include:

We currently carry two GLP-1 options for patients managing type 2 diabetes:

Victoza (Liraglutide Injection)

View Victoza →

Victoza is a once-daily injection that was the first GLP-1 approved for cardiovascular risk reduction (LEADER trial, 2016). It reduces A1C by 1–1.5% and carries a well-established 15+ year safety record.

• Indications: Type 2 diabetes, CV risk reduction in T2D patients with heart disease
• Doses: 0.6 mg (starter) → 1.2 mg → 1.8 mg/day
• Best for: Patients wanting a daily injectable with strong CV data

Rybelsus (Oral Semaglutide Tablet)

View Rybelsus →

Rybelsus is the only oral GLP-1 medication currently available. It contains the same active molecule as Ozempic (semaglutide), but in tablet form — a significant advantage for patients who prefer to avoid injections.

• Indications: Type 2 diabetes management
• Doses: 3 mg (starter, 30 days) → 7 mg → 14 mg
• Critical dosing note: Take on an empty stomach with no more than 4 oz (120 mL) of plain water, at least 30 minutes before the first food, drink, or other medications of the day. Bioavailability drops to near zero if taken with food.
• Best for: Injection-averse patients, those new to GLP-1 therapy

GLP-1 Medications for Weight Loss

While GLP-1 drugs were originally designed for diabetes, weight loss emerged as a major secondary effect in clinical trials — and for some agents, the primary FDA-approved indication.

Drug	FDA Weight Loss Approval?	Average Weight Loss in Trials
Wegovy (semaglutide 2.4mg)	✅ Yes (2021)	14.9% (STEP 1 trial)
Zepbound (tirzepatide 10/15mg)	✅ Yes (2023)	20.9–22.5% (SURMOUNT-1)
Saxenda (liraglutide 3mg)	✅ Yes (2014)	8%
Ozempic (semaglutide 1mg/2mg)	❌ No (T2D only)	~10–14% (off-label)
Rybelsus	❌ No (T2D only)	~4–5%
Victoza	❌ No (T2D only)	~3–6%

Note on off-label use: Ozempic is widely prescribed off-label for weight loss in people without diabetes. This is legal practice in the US, but Ozempic is not FDA-approved for obesity. Wegovy (same molecule, higher dose) is the FDA-approved formulation for weight management.

Cardiovascular Benefits of GLP-1 Medications

Multiple large-scale cardiovascular outcome trials (CVOTs) have demonstrated that certain GLP-1 drugs reduce the risk of major adverse cardiac events (MACE) in high-risk patients:

Trial	Drug	Reduction in MACE
LEADER (2016)	Liraglutide (Victoza)	13% relative risk reduction
SUSTAIN-6 (2016)	Semaglutide (Ozempic)	26% relative risk reduction
REWIND (2019)	Dulaglutide (Trulicity)	12% relative risk reduction
SELECT (2023)	Semaglutide (Wegovy)	20% reduction in MACE (non-diabetic obese patients)

The SELECT trial result is particularly significant: it was the first to show cardiovascular protection from a weight loss drug in patients without diabetes — expanding the potential use of semaglutide far beyond its original indication.

What’s New in GLP-1 Medications in 2026

Oral GLP-1 Revolution

The biggest shift in 2026 is the expansion of oral GLP-1 options. Rybelsus (oral semaglutide) has been available since 2019 for type 2 diabetes. The first oral semaglutide formulation approved specifically for obesity was cleared by the FDA in late 2025, expected to reach pharmacies in Q2 2026. Eli Lilly is simultaneously running Phase 3 trials for oral tirzepatide.

This shift from weekly injections to daily pills is expected to dramatically expand the patient population using GLP-1 therapy.

Retatrutide: The “Triple G” Drug

The most-watched drug in the GLP-1 pipeline is retatrutide (Eli Lilly), which activates three hormone receptors simultaneously: GLP-1, GIP, and glucagon. In Phase 3 trials, the highest dose produced 28.7% average weight loss at 68 weeks — nearly double what semaglutide achieves. Seven additional Phase 3 trial results are expected through 2026, with potential FDA submission in 2027.

Retatrutide is not FDA-approved and not legally available for prescription as of March 2026.

FDA Crackdown on Compounded GLP-1s

In February 2026, the FDA announced enforcement action against telehealth companies and compounding pharmacies marketing non-FDA-approved GLP-1 formulations. Semaglutide was removed from the FDA drug shortage list (February 21, 2026), eliminating the legal basis for compounding. Patients who relied on compounded semaglutide are transitioning back to branded Ozempic, Wegovy, and Rybelsus.

Common Side Effects of GLP-1 Medications

GLP-1 receptor agonists share a common side effect profile across the class:

Most common (reported in >10% of patients):

• Nausea (most frequent, especially during dose escalation)
• Vomiting
• Diarrhea
• Constipation
• Decreased appetite

Less common but important:

• Injection site reactions (for injectable forms)
• Increased heart rate (5–10 bpm average)
• Headache
• Fatigue

Serious warnings (FDA Boxed Warning):

• Thyroid C-cell tumors — Observed in rodent studies. Contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• Pancreatitis — Discontinue if suspected.

Most gastrointestinal side effects are dose-dependent and transient, typically resolving within 4–8 weeks as the body adapts. Starting with the lowest dose and titrating slowly significantly reduces GI side effects.

GLP-1 Medications Cost & How to Save

GLP-1 drugs are among the most expensive prescription medications in the US:

Drug	List Price (US, per month)	With Manufacturer Coupon
Ozempic 1mg	~$935	~$25 (with insurance)
Wegovy 2.4mg	~$1,350	~$0–25 (limited)
Rybelsus 14mg	~$870	~$10–25 (with insurance)
Victoza 1.8mg	~$680	Manufacturer PAP available
Mounjaro 15mg	~$1,069	~$25 (with insurance)

Cost-reduction options:

• Manufacturer savings programs — Novo Nordisk and Eli Lilly offer $0–25/month copay cards for commercially insured patients
• Canadian pharmacy — Licensed Canadian pharmacies offer significantly lower prices for the same brand-name medications
• GoodRx — Discount codes at US retail pharmacies
• Insurance prior authorization — Most insurers require documented A1C levels and prior therapy failure

Frequently Asked Questions

Medical Disclaimer

Medical Disclaimer: The information on this page is intended for educational purposes only and does not constitute medical advice. GLP-1 medications are prescription drugs — they require evaluation and a prescription from a licensed healthcare provider. Do not start, stop, or change any medication without consulting your doctor or pharmacist. Canadian Health Care Mall dispenses medications only upon presentation of a valid prescription from a licensed prescriber.

Clinical References